Company: TAK
Filing Date: 2025-03-26
Form Type: 6-K
Source: 0001395064-25-000038
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-03-26
Form: 6-K
Chunk 1
---
 president of the U.S. Business Unit and U.S. country head, will succeed Christophe Weber as Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Takeda’s Board of Directors will propose Mrs. Kim as a new candidate for election to the Board at the 150th Ordinary General Meeting of Shareholders to be held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.

* Please refer to “Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026”

Note:

1. The role of the directors who are not Audit and Supervisory Committee Members will be determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.

2. The members of the Nomination Committee and Compensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 149th Ordinary General Meeting of Shareholders.

#### About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contacts:

Global Media

Brendan Jennings

brendan.jennings@takeda.com

+81 80-2705-8259

#### Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise